Thermo Fisher Scientific Inc. $TMO Stock Position Lifted by Wedge Capital Management L L P NC

Key Points

• Wedge Capital Management significantly increased its stake in Thermo Fisher Scientific Inc. by 139% during the second quarter, holding 17,847 shares valued at approximately $7.24 million.
• Multiple institutional investors, including Vanguard Group and UBS AM, have also increased their holdings, reflecting strong institutional interest in the company.
• Thermo Fisher Scientific reported earnings of $5.36 per share in its latest quarter, exceeding analyst expectations while setting its Q3 2025 guidance between $5.460 and $5.510 EPS.

Wedge Capital Management L L P NC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 139.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,847 shares of the medical research company's stock after acquiring an additional 10,381 shares during the period. Wedge Capital Management L L P NC's holdings in Thermo Fisher Scientific were worth $7,236,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC boosted its position in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares during the period. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth $30,000. Finally, Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TMO shares. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $1.03 during midday trading on Tuesday, hitting $473.97. The company's stock had a trading volume of 1,918,458 shares, compared to its average volume of 2,391,367. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The firm's fifty day moving average price is $472.99 and its 200-day moving average price is $448.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $178.97 billion, a P/E ratio of 27.40, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.